when and how to switch How I treat with anticoagulants in 2012: new and old anticoagulants, and

Summary of Product Char-acteristics : Pradaxa ( dabigatran etexilate ). Lon-don, United Kingdom: European MedicinesAgency; 2008:1-10.24. Liesenfeld KH, Lehr T, Dansirikul C, et al. Popula-tion pharmacokinetic analysis of the oral thrombininhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost. 2011;9(11):2168-2175.25. European MedicinesAgency. Pradaxa. Proce-dural steps taken and scientific information afterthe authorisation. http://www.ema.europa.eu/humandocs/PDFs/EPAR/pradaxa/H-829-en8.pdf.Accessed March 20, 2010.26. Oldgren J, BudajA, Granger CB, et al. Dabiga-tran vs. placebo in patients with acute coronarysyndromes on dual antiplatelet therapy: a ran-domized, double-blind, phase II trial. Eur Heart J. 2011;32(22):2781-2789.27. Mega JL, Braunwald E, Wiviott SD, et al. Rivar-oxaban in patients with a recent acute coronarysyndrome. N Engl J Med. 2012;366(1):9-19.28. Alexander JH, Becker RC, Bhatt DL, et al.Apixa-ban, an oral, direct, selective factor Xa inhibitor, incombination with antiplatelet therapy after acutecoronary syndrome: results of theApixaban forPrevention ofAcute Ischemic and Safety Events(APPRAISE) trial.

[1]  Paul Burton,et al.  Rivaroxaban in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.

[2]  S. Heiland,et al.  Hemostatic Therapy in Experimental Intracerebral Hemorrhage Associated With the Direct Thrombin Inhibitor Dabigatran , 2011, Stroke.

[3]  S. Yusuf,et al.  Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial , 2011, Journal of thrombosis and haemostasis : JTH.

[4]  F. Van de Werf,et al.  Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. , 2011, European heart journal.

[5]  T. Fleming,et al.  Evaluating rivaroxaban for nonvalvular atrial fibrillation--regulatory considerations. , 2011, The New England journal of medicine.

[6]  Flor A. Cianchetti,et al.  Anticoagulation With the Oral Direct Thrombin Inhibitor Dabigatran Does Not Enlarge Hematoma Volume in Experimental Intracerebral Hemorrhage , 2011, Circulation.

[7]  P. Kamphuisen,et al.  Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects , 2011, Circulation.

[8]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[9]  Deepak L. Bhatt,et al.  Apixaban with antiplatelet therapy after acute coronary syndrome. , 2011, The New England journal of medicine.

[10]  W. Ageno,et al.  Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists , 2011, Thrombosis and Haemostasis.

[11]  L. Baruch,et al.  Potential Inaccuracy of Point-of-Care INR in Dabigatran-Treated Patients , 2011, The Annals of pharmacotherapy.

[12]  S. Yusuf,et al.  Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial , 2011, Circulation.

[13]  R. P. Zhu,et al.  Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation , 2011, Annals of Internal Medicine.

[14]  Kenneth A Ellenbogen,et al.  2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, Journal of the American College of Cardiology.

[15]  Kenneth A Ellenbogen,et al.  2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, Heart rhythm.

[16]  M. Levi,et al.  Safety of recombinant activated factor VII in randomized clinical trials. , 2010, The New England journal of medicine.

[17]  Salim Yusuf,et al.  Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial , 2010, The Lancet.

[18]  C. Stöllberger,et al.  The frequency of prescription of P‐glycoprotein‐affecting drugs in atrial fibrillation , 2010, Journal of thrombosis and haemostasis : JTH.

[19]  J. Douketis,et al.  Periprocedural anticoagulation practices in warfarin-treated patients who require elective angiography with or without percutaneous coronary intervention: a retrospective chart review. , 2010, Thrombosis research.

[20]  M. Feuring,et al.  Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity , 2010, Thrombosis and Haemostasis.

[21]  Elisabeth Perzborn,et al.  Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor , 2010, Thrombosis and Haemostasis.

[22]  S. Goldhaber,et al.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism. , 2009, The New England journal of medicine.

[23]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[24]  W. Ageno,et al.  Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. , 2009, Blood.

[25]  J. Mega,et al.  Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial , 2009, The Lancet.

[26]  Deepak L. Bhatt,et al.  Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial , 2009, Circulation.

[27]  J. Douketis,et al.  The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[28]  T. Ebner,et al.  The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans , 2008, Drug Metabolism and Disposition.

[29]  K. Rathgen,et al.  The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. , 2007, British journal of clinical pharmacology.

[30]  S. Schulman,et al.  Anticoagulants and their reversal. , 2007, Transfusion medicine reviews.

[31]  Michael Becka,et al.  Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects , 2005, European Journal of Clinical Pharmacology.

[32]  G. Wensing,et al.  Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59‐7939, an oral, direct factor Xa inhibitor , 2005, Clinical pharmacology and therapeutics.

[33]  A. Turpie,et al.  Perioperative bridging interruption with heparin for the patient receiving long-term anticoagulation , 2005, Current opinion in pulmonary medicine.

[34]  Treatment of venous thromboembolism with vitamin K antagonists: patients' health state valuations and treatment preferences. , 2004, Thrombosis and haemostasis.

[35]  M. Wolzt,et al.  Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers , 2004, Thrombosis and Haemostasis.

[36]  S. Carlsson,et al.  Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. , 2001, Thrombosis research.

[37]  P. Contu,et al.  The Management of Oral Anticoagulant Therapy: The Patient’s Point of View , 2000, Thrombosis and Haemostasis.

[38]  D. Singer,et al.  The impact of long-term warfarin therapy on quality of life. Evidence from a randomized trial. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. , 1991, Archives of internal medicine.